Comparative Pharmacology
Head-to-head clinical analysis: HICON versus METHSCOPOLAMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus METHSCOPOLAMINE BROMIDE.
HICON vs METHSCOPOLAMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Antimuscarinic agent that competitively antagonizes acetylcholine at muscarinic receptors, inhibiting gastrointestinal motility and secretions.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
2.5 to 5 mg orally three times daily and at bedtime; or 0.25 to 1 mg subcutaneously or intramuscularly every 6 to 8 hours.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Clinical Note
moderateMethscopolamine bromide + Topiramate
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Topiramate."
Clinical Note
moderateMethscopolamine bromide + Methadone
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Methadone."
Clinical Note
moderateMethscopolamine bromide + Mirabegron
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Mirabegron."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5-2 hours in adults; clinical context: requires frequent dosing (every 4-6 hours) to maintain therapeutic effect.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% excreted in urine within 24 hours, with the remainder eliminated in feces via biliary excretion.
Category C
Category A/B
Anticholinergic
Anticholinergic
Methscopolamine bromide + Sufentanil
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Sufentanil."